Chemours Co
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
CC$13.48+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2025 and 2024
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $670 | $713 |
| Restricted cash and restricted cash equivalents | 2 | — |
| Accounts and notes receivable, net | 679 | 770 |
| Inventories | 1,569 | 1,463 |
| Prepaid expenses and other | 80 | 71 |
| Assets held for sale | 1 | — |
| Total current assets | 3,001 | 3,017 |
| Property, plant, and equipment | 9,920 | 9,577 |
| Less: Accumulated depreciation | (6,842) | (6,389) |
| Property, plant, and equipment, net | 3,078 | 3,188 |
| Operating lease right-of-use assets | 271 | 265 |
| Goodwill | 46 | 46 |
| Other intangible assets, net | 2 | 3 |
| Investments in affiliates | 160 | 152 |
| Assets held for sale, non-current | 21 | — |
| Restricted cash and restricted cash equivalents | 52 | 50 |
| Other assets | 751 | 788 |
| Total assets | $7,382 | $7,509 |
| Liabilities | ||
| Current liabilities: | ||
| Accounts payable | $954 | $1,156 |
| Compensation and other employee-related cost | 96 | 99 |
| Short-term and current maturities of long-term debt | 42 | 54 |
| Current environmental remediation | 88 | 115 |
| Other accrued liabilities | 506 | 396 |
| Total current liabilities | 1,686 | 1,820 |
| Long-term debt, net | 4,099 | 4,059 |
| Operating lease liabilities | 191 | 198 |
| Long-term environmental remediation | 530 | 456 |
| Deferred income taxes | 37 | 35 |
| Other liabilities | 588 | 369 |
| Total liabilities | 7,131 | 6,937 |
| Commitments and contingent liabilities | ||
| Equity | ||
| Common stock (par value $0.01 per share; 810,000,000 shares authorized; 198,720,786 shares issued and 149,893,993 shares outstanding at December 31, 2025; 198,300,033 shares issued and 149,428,431 shares outstanding at December 31, 2024) | 2 | 2 |
| Treasury stock, at cost (48,826,793 shares at December 31, 2025; 48,871,602 shares at December 31, 2024) | (1,802) | (1,804) |
| Additional paid-in capital | 1,074 | 1,055 |
| Retained earnings | 1,220 | 1,685 |
| Accumulated other comprehensive loss | (244) | (367) |
| Total Chemours stockholders’ equity | 250 | 571 |
| Non-controlling interests | 1 | 1 |
| Total equity | 251 | 572 |
| Total liabilities and equity | $7,382 | $7,509 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.